Wedbush cuts target for BioCryst stock from USD 20.00 to USD 18.00
Published on 10/27/2026 at 21:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst target and reporting date
- Wedbush cut its BioCryst target from USD 20.00 to USD 18.00 on October 19, 2026.
- Second-quarter 2026 revenue reached USD 218.25 million against USD 163.35 million a year earlier.
- BioCryst stock costs EUR 7.18 at Lang & Schwarz on October 27, 2026 at 9:56 p.m. CEST, 2.57 percent above the Frankfurt close of October 26, 2026.
- BioCryst plans to report third-quarter 2026 results on November 4, 2026.
On October 19, 2026, Wedbush cut its BioCryst Pharmaceuticals target from USD 20.00 to USD 18.00 while keeping an Outperform rating, as Yahoo Finance reported. The move gives the latest analyst view a concrete valuation marker. BioCryst stock was trading at EUR 7.18 at Lang & Schwarz on October 27, 2026 at 9:56 p.m. CEST, up 2.57 percent versus the Frankfurt close of October 26, 2026 at EUR 7.00.
Target remains above the Nasdaq price
The USD 18.00 target sits 55.00 percent above the Nasdaq last price of USD 8.10 on October 27, 2026 at 4:00 p.m. ET. That comparison is separate from the euro quotation and shows why the analyst revision still leaves a wide valuation gap.
Revenue provides the operating anchor
BioCryst reported USD 218.25 million of revenue for the second quarter of 2026, compared with USD 163.35 million a year earlier. Net income reached USD 78.40 million for the quarter against USD 5.09 million in the comparable period, according to Markets Insider.
November 4 brings the next report
BioCryst is scheduled to report third-quarter 2026 financial results on November 4, 2026, a date carried in the company news references shown by Markets Insider. The upcoming report will give investors a fresh test of revenue growth and profitability after the second-quarter figures.
Price range puts the move in context
The Nasdaq range for the latest year runs from USD 6.23 to USD 11.22, with the stock at USD 8.10 on October 27, 2026. Trading volume reached 8,705,308 shares, while market capitalization stood at USD 2.1 billion on the same date. The euro quote is therefore above its Frankfurt close, but the broader US range remains the more useful valuation frame.
BioCryst price snapshot
At Lang & Schwarz, BioCryst Pharmaceuticals was trading at EUR 7.18 on October 27, 2026 at 9:56 p.m. CEST, 2.57 percent above the Frankfurt close of October 26, 2026 at EUR 7.00.
The further course of trading is shown by the continuously updated real-time quote of BioCryst Pharmaceuticals stock.
BioCryst Pharmaceuticals market data
- Company: BioCryst Pharmaceuticals, Inc.
- ISIN: US09058V1035
- Ticker: BCRX
- Primary exchange: Nasdaq
- Price Lang & Schwarz (as of October 27, 2026, 9:56 p.m. CEST): EUR 7.18
- Change versus Frankfurt close: plus 2.57 percent
- Frankfurt close (October 26, 2026): EUR 7.00
- Market capitalization: USD 2.1 billion (as of October 27, 2026)
- 52-week range: USD 6.23-11.22 (as of October 27, 2026)
- Sector / Industry: Healthcare / Biotechnology
- Next earnings date: November 4, 2026
Market context: Market report S&P 500.
